Volume 2.00 | Jan 8

Immune Regulation News 2.00, January 8, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Dampening CD4+ Immune Cell Function Via the Protein TLR4
University of California scientists have determined that triggering TLR4 on CD4+ T cells dampens their inflammatory function, as TLR4 deficiency in two mouse models of colitis accelerated the development of disease and/or induced more severe disease. [University of California, La Jolla] 

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®
 
 
REQUEST A POSTER STEMCELL Technologies Inc
 


SPECIAL FEATURE


Video: The EasySep® Pour-off – A Simple and Effective Way to Isolate Cells


SCIENCE NEWS

Enzyme’s Key Role in Regulating Immune System
Mice lacking an enzyme known as deoxycytidine kinase have defects in their adaptive immune system, producing very low levels of both T and B lymphocytes, the major players involved in immune response. [University of California, Los Angeles]

Inflammatory Mediator Regulates Diarrhea in Inflammatory Bowel Disease
The activation of NF-kappaB, an inflammatory mediator, results in diarrhea in inflammatory bowel disease. [Northwestern University, Chicago]

What Is The Function Of The Protein CD20?

A team of researchers from The Netherlands, has determined that CD20 has a nonredundant role in generating optimal B cell immune responses by analyzing a patient lacking the protein. [Academic Medical Center, Amsterdam]

NegSelRosetteSep_645x110_v01



CURRENT PUBLICATIONS

CTLA-4 Suppresses the Pathogenicity of Self Antigen-Specific T Cells by Cell-Intrinsic and Cell-Extrinsic Mechanisms
Results demonstrate that both cell-intrinsic and non-cell-autonomous actions of CTLA-4 operate to maintain T cell tolerance to a self antigen. [Nat Immunol]


TLR4 Signaling in Effector CD4+ T Cells Regulates TCR Activation and Experimental Colitis in Mice
Researchers show that TLR4 triggering on CD4+ T cells affects their phenotype and their ability to provoke intestinal inflammation. [J Clin Invest]


Expansion of FOXP3+ CD8 T cells with Suppressive Potential in Colorectal Mucosa Following a Pathogenic Simian Immunodeficiency Virus Infection Correlates with Diminished Antiviral T Cell Response and Viral Control
This study suggests an important but previously unappreciated role for CD8 regulatory T cells in suppressing antiviral immunity during immunodeficiency virus infections. [J Immunol]


CD137 Promotes Proliferation and Survival of Human B Cells
CD137 (4-1BB)-mediated costimulation plays an important role in directing the fate of antigen-stimulated T cells and natural killer cells, yet the role of CD137 in mediating B cell function is unknown. This study suggests that CD137 costimulation may play a role in defining the fate of antigen-stimulated human B cells. [J Immunol]


CTLA4Ig Alters the Course of Autoimmune Disease Development in Lyn-/- Mice
Results suggest that when self-reactive B cell clones are unimpeded in acquiring T cell help, they secrete pathogenic IgG autoantibodies that trigger the fulminant autoimmunity normally observed in Lyn-/- mice. [J Immunol]

Ins2 Deficiency Augments Spontaneous HLA-A*0201-Restricted T Cell Responses to Insulin
In humans, the non-MHC locus conferring the strongest Type 1 diabetes disease susceptibility is the insulin gene, and alleles yielding lower thymic insulin expression are predisposing.  Researchers sought to incorporate this characteristic into an HLA-transgenic model of the disease and to determine the influence of reduced thymic insulin expression on CD8+ T cell responses to preproinsulin. [J Immunol]

RoboSep_645x110_v01



INDUSTRY NEWS

Teva Sees Revenue More than Doubling by 2015
Teva Pharmaceutical Industries Ltd., the world’s largest generic drugmaker, set a target of revenue of $31 billion in 2015, more than double its current annual amount as it sees major growth in overall use of generics.

Athersys Inc. Shares More Than Double on Pfizer Agreement to Develop Inflammatory Bowel Disease Therapy
Biopharmaceutical company Athersys Inc. is in line for up to $111 million in revenue through an agreement with a Pfizer Inc. unit to develop and market a stem cell therapy for patients who suffer from inflammatory bowel disease.

Michigan Biotech Startup Lycera Moving Headquarters to Massachusetts
The University of Michigan spinoff, which raised a $36 million Series A round of funding last year, plans to maintain its research and development operations in Plymouth, according to a statement from the company.

POLICY NEWS

Cancellation of Notice NOT-CA-09-017, Clarification of Page Limitations for Research Plan in PAR-09-026 Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment (U01) (NOT-OD-10-029) [National Institutes of Health, United States]

Notice on P40 Page Limits (NOT-RR-10-002) [National Institutes of Health, United States]

Academic Research Enhancement Award (Parent R15) (PA-10-070) [National Institutes of Health, United States]

Technologies and Software to Support Integrative Cancer Biology Research (R43/R44) [Small Business Innovation Research, United States]

EVENTS

9th International Conference on New Trends in Immunosuppression and Immunotherapy
February 4-6, 2010
Geneva, Switzerland

13th International Conference on Lymphocyte Activation and Immune Regulation: Inflammasome and Inflammation
February 5-7, 2010
Newport Beach, United States

Keystone Symposia: Tolerance and Autoimmunity
February 21-26, 2010
Taos, United States

World Immune Regulation Meeting – IV
March 29-April 1, 2010
Davos, Switzerland

IMMUNOLOGY 2010
May 7-11, 2010
Baltimore, United States

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES


Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Data Entry Assistant – Marketing (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.


Have we missed an important article or publication in Immune Regulation News? Click here to submit!

 

Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us